Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial

The objective of this study is to evaluate the efficacy and safety of ambrisentan in PoPH.

Source: The Journal of Heart and Lung Transplantation - January 20, 2020 Category: Transplant Surgery Authors: Ioana R. Preston, Charles D. Burger, Sonja Bartolome, Zeenat Safdar, Michael Krowka, Namita Sood, Hubert J. Ford, Wejdan F. Battarjee, Murali M. Chakinala, Mardi Gomberg-Maitland, Nicholas S. Hill Tags: ORIGINAL CLINICAL SCIENCE Source Type: research